Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-NY-ESO-1 TCR-transduced T cells
- Development stage
- Unknown
- Lead developer
- Shenzhen Second People’s Hospital
- Modality
- TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
Anti-NY ESO-1 TCR-transduced T cells is an autologous adoptive T-cell therapy developed by Shenzhen Second People's Hospital. The therapy involves isolating peripheral blood mononuclear cells (PBMCs) from a patient and engineering them using a lentiviral or retroviral vector to express a T-cell receptor (TCR) specific for the NY-ESO-1 (New York Esophageal Squamous Cell Carcinoma-1) cancer-testis antigen. Specifically, the TCR is HLA-A2-restricted and targets the NY-ESO-1:157-165 epitope. After in vitro expansion, the engineered T cells are infused back into the patient following a lymphodepleting preconditioning regimen. This investigational biologic is being evaluated in Phase I clinical trials for various HLA-A2-positive, NY-ESO-1-expressing relapsed or refractory malignancies, including synovial sarcoma, melanoma, and multiple myeloma.
- Other names
- NY-ESO-1 TCR-T cellsNY-ESO1 TCR-T cellsNY-ESO 1 TCR-T cellsanti-NY-ESO-1 TCR-transduced T cellsanti-NY-ESO1 TCR-transduced T cellsanti-NY-ESO 1 TCR-transduced T cells
02
Targets
pMHC-I (Peptide–MHC class I complex)
Beyond the preview
Go deeper on anti-NY-ESO-1 TCR-transduced T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-NY-ESO-1 TCR-transduced T cells.